embecta partners with Direct Relief to extend humanitarian mission
By HME News Staff
Updated 10:26 AM CST, Mon November 17, 2025
PARSIPPANY, N.J. - embecta Corp., a large manufacturer of insulin injection devices, has expanded its partnership with Direct Relief, a leading humanitarian aid organization and large charitable insulin provider in the United States. Through 2026, embecta's diabetes products, including syringes, pen needles, and diabetes management supplies, will reach patients who cannot afford insurance and do not qualify for Medicaid, ensuring they have consistent, uninterrupted access to the tools essential for managing their diabetes. "As we mark World Diabetes Day, embecta is proud to deepen our commitment to ensuring that everyone living with diabetes—regardless of their ability to pay or where they live—has access to the supplies they need," said Dev Kurdikar, CEO, embecta. "Since becoming an independent company, we have focused on empowering people with diabetes while paving the way for a life unlimited for all. This partnership with Direct Relief helps extend that mission to those who need it most." After embecta spun off from BD in 2022, BD-branded pen needles and insulin syringes became part of its portfolio. In 2025, embecta rebranded packaging in North America and donated about 15 million units of the previous BD-branded devices to Direct Relief. Direct Relief partners with more than 1,600 community health centers and free and charitable clinics across all 50 states, the District of Columbia and Puerto Rico, serving more than 36 million patients, including one in five of America’s uninsured.
Comments